# Worldwide Healthcare Trust H1 2026 results impress with 14.8% total return (LON: WWH)

- Link: https://www.directorstalkinterviews.com/worldwide-healthcare-trust-h1-2026-results-impress-with-14-8-total-return-lon-wwh/4121270159
- Published: 2026-11-20T13:04:56+00:00
- Author: Amilia Stone

**Worldwide Healthcare Trust PLC** (LON:WWH) has announced its Unaudited Results
for the Six Months ended 30 September 2026

The statements below are extracted from the Company’s half-year report for the six
months ended 30 September 2026. This announcement contains references to graphs 
and charts which appear in the full Half Year Report, which will shortly be available
on the Company’s website: www.worldwidewh.com where up to date information on the
Company, including daily NAV, share prices and fact sheets, can also be found.

The Half Year Report has been submitted to the Financial Conduct Authority, and 
will shortly be available for inspection on the National Storage Mechanism (NSM)
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

## Performance

|   |   | **SIX MONTHS TO** | **ONE YEAR TO** | 
|   |   | **30 SEPTEMBER** | **31 MARCH** | 
|   |   | **2026** | **2026** | 
| Net asset value per share (total return)* # |   | +9.3% | +10.0% | 
| Share price (total return)* # |   | +14.8% | +13.1% | 
| Benchmark (total return)^ # |   | +9.9% | +1.8% |

|   | **30 SEPTEMBER** | **31 MARCH** | **SIX MONTHS** | 
|   | **2026** | **2026** | **CHANGE** | 
| Net asset value per share | 403.6p | 371.0p | +8.8% | 
| Share price | 381.5p | 334.0p | +14.2% | 
| Discount of share price to the net asset value per share | (5.5)% | (10.0)% |   | 
| Leverage^(1) | 14.9% | 12.5% |   | 
| Ongoing charges* | 0.9% | 0.9% |   | 
| Ongoing charges (including performance fees crystallised during the period)* | 0.9% | 0.9% |   |

# Source – Morningstar.

^ Benchmark – MSCI World Health Care Index on a net total return, sterling adjusted
basis (see Glossary).

* Alternative Performance Measure (See Glossary).

^(1) Leverage calculated under the Commitment Method (see Glossary).

> **Statement from the Chair**
> **“During the first half of the financial year, the Company’s net asset value 
> per share total return was +9.3% and the share price total return was +14.8%, 
> these compared to a return of +9.9% from the Company’s Benchmark.”**

This is my first statement to shareholders of Worldwide Healthcare Trust PLC following
my appointment as Chair at the conclusion of the Company’s Annual General Meeting(“
AGM”) in July 2026. I am pleased to report that, against a backdrop of ongoing economic
and geopolitical uncertainty, the Healthcare sector’s long-term fundamentals remain
compelling. Innovation across Pharmaceuticals, Biotechnology and Healthcare Services
continues to create attractive opportunities for active investors. While market 
sentiment towards Healthcare stocks remained variable during the period, the Board
remains confident in the Company’s investment approach and long-term prospects.

**PERFORMANCE**

During the six-month period, global markets continued to be influenced by the evolving
macroeconomic environment, the trajectory of interest rates, geopolitical developments
and the ongoing impact of artificial intelligence-related investment. Whilst broader
equity markets remained supported by resilient economic activity and generally healthy
corporate earnings, investor sentiment continued to fluctuate in response to policy
developments and concerns regarding economic growth in several major regions.

Against this backdrop, the performance of the Healthcare sector, which underperformed
the broader market in the period, reflected a combination of policy, regulatory 
and company-specific factors. While the sector continued to benefit from strong 
levels of innovation, particularly in Biotechnology and precision medicine, investor
attention (particularly in the first few months of the financial year) remained 
focused on issues such as drug pricing and the pace of regulatory approvals. Merger
and acquisition activity remained an important feature of the Healthcare landscape,
providing support for valuations across selected areas of the market.

In this environment, I am pleased to report that the Company’s net asset value (“
NAV”) per share total return during the six months to 30 September 2026 was +9.3%,
and the share price total return was 14.8%, these compared to a net total return
of +9.9% from the Company’s Benchmark, the MSCI World Health Care Index (sterling-
adjusted), during the same period. The discount of the Company’s share price to 
the NAV per share discount moved from 10.0% to 5.5% during the half year.

The Portfolio Manager continued to identify attractive opportunities across Healthcare
subsectors and geographies while also maintaining the Company’s long-standing emphasis
on innovation, scientific advancement and long-term growth potential.

Looking at specific names in the portfolio, the top two contributions came from 
U.S. Pharmaceutical major **Eli****Lilly** and U.S. Biotechnology company **Natera**.
Theportfolio’s proprietary swap basket of Biotechnology companies with the potential
to be acquired also made a positive contribution to performance during the period.
Meanwhile, the two principal detractors from performance were U.S. Medical Technology
company **Boston Scientific** and Swedish-British multinational Pharmaceutical and
Biotechnology company **AstraZeneca**. Further information on the Company’s investments
and performance can be found in the Portfolio Manager’s Review.

As shareholders will be aware, leverage remains an important component of the Company’s
investment approach. Average leverage during the period was 14.9%, contributing 
1.1% to overall performance. At the half-year end, leverage stood at 14.9%, compared
with 12.5% at the start of the period.

**PERFORMANCE FEE**

No performance fee was accrued as at 30 September 2026 and no performance fee can
become payable within the next year. The performance fee arrangements are described
in detail in the Company’s Annual Report.

**CAPITAL**

Share price discounts continued to be a prominent feature of the investment company
sector during the period. As noted above, the Company’s discount to NAV stood at
5.5% on 30 September 2026, this compares to an average share price discount in the
sector of 11.8%. (source: Winterflood Investment Trusts).

The Board’s policy remains to repurchase shares when the Company’s discount to NAV
exceeds 6% on an ongoing basis. Despite the Company’s share buybacks, the discount
can remain greater than 6% for extended periods of time, depending on overall sentiment
towards the Company, the sector and investment companies generally. Whilst share
buybacks cannot entirely offset wider market sentiment towards investment companies,
they enhance NAV per share for continuing shareholders and remain an important mechanism
in the management of the discount.

During the period, the Company repurchased a total of 31,330,075 shares for treasury
at a cost of £115.9m and at an average discount of 7.2%. At the period end, there
were 342,082,342 shares in issue (excluding the 259,582,858 shares held in treasury).
From the period end to 16 November 2026, a further 7,776,867 shares have been bought
back for treasury, at a cost of £30.0m and at an average discount of 7.5%.

The Board remains committed to its discount control policy and will continue to 
monitor market conditions closely while balancing the interests of both existing
and prospective shareholders.

The Company’s share buyback authority will, as usual, be proposed for renewal at
the Company’s AGM to be held on Tuesday,13 July 2027.

**DIVIDENDS**

The Board has declared an unchanged interim dividend of 0.7p per share, for the 
year to 31 March 2027. It will be payable on 8 January 2027 to shareholders on the
register of members on 27 November 2026, with an ex-dividend date of 26 November
2026.

The Board continues to believe that shareholders’ long-term interests are best served
by maximising opportunities for capital growth through investment in the portfolio
rather than targeting a particular dividend yield. Accordingly, the Company’s dividend
policy remains focused on maintaining investment trust status and distributing income
in accordance with applicable requirements.

**COMPOSITION OF THE BOARD AND PORTFOLIO MANAGEMENT RESPONSIBILITIES**

As I have mentioned, I succeeded Doug McCutcheon as Chair of the Board when he retired
from the Board at the conclusion of the AGM in July. On behalf of the Board and 
Shareholders, I would like to thank Doug for his leadership, commitment and the 
hugely valuable contribution he made to the Company throughout his tenure.

We also announced, in August, that Sven Borho was stepping down as the Company’s
lead portfolio manager, and he retired from the Board on 30 October 2026. Sven was
involved in the growth and strategy of the Company since its inception in 1995 and
served as a Director for the last eight years. On behalf of the Board, I would like
to express gratitude to Sven for his significant efforts on behalf of the Company
throughout that time.

We shall miss the contributions of Doug and Sven, both in Board meetings, and outside.

We were, however, delighted that Trevor Polischuk, who was previously co-portfolio
manager with Sven, agreed to take on the role of lead portfolio manager in August
and we announced the appointment of Geoff Hsu as his co-portfolio manager at the
same time. Trevor and Geoff both know the Company’s portfolio well and the Company’s
investment approach has not changed as a result of Sven’s retirement.

**OUTLOOK**

The Board remains confident in the long-term investment case for the global Healthcare
sector.

Healthcare continues to benefit from powerful structural growth drivers, including
ageing populations, rising Healthcare expenditure, increasing demand for innovative
therapies and rapid advances in medical science and technology. In addition, the
pace of innovation across areas such as oncology, obesity treatments, precision 
medicine and artificial intelligence-enabled Healthcare remains compelling.

Whilst periods of market volatility are likely to persist, the Board believes that
current valuations across parts of the Healthcare sector continue to present attractive
opportunities for active investors. We therefore remain confident in the Portfolio
Manager’s ability to generate attractive long-term returns through disciplined stock
selection and effective capital allocation.

As I begin my tenure as Chair, I do so with confidence in the Company’s strategy,
the strength and depth of its portfolio, and the expertise of the Portfolio Manager,
all set against this positive backdrop for the Healthcare sector.

I look forward to engaging with shareholders in the years ahead and thank you for
your continued support of the Company.

**William Hemmings**

Chair

17 November 2026

[274530-wwh-web](https://www.directorstalkinterviews.com/wp-content/uploads/2026/11/274530-wwh-web.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2026/11/274530-wwh-web.pdf)

Share on:
